IL161802A0 - Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical applicatio - Google Patents
Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical applicatioInfo
- Publication number
- IL161802A0 IL161802A0 IL16180202A IL16180202A IL161802A0 IL 161802 A0 IL161802 A0 IL 161802A0 IL 16180202 A IL16180202 A IL 16180202A IL 16180202 A IL16180202 A IL 16180202A IL 161802 A0 IL161802 A0 IL 161802A0
- Authority
- IL
- Israel
- Prior art keywords
- species
- gram
- cocci
- positive
- fungicide
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 2
- 230000003385 bacteriostatic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000855 fungicidal effect Effects 0.000 title abstract 2
- 239000000417 fungicide Substances 0.000 title abstract 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- 241000304886 Bacilli Species 0.000 abstract 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 abstract 1
- 241000589291 Acinetobacter Species 0.000 abstract 1
- 241000607534 Aeromonas Species 0.000 abstract 1
- 241000228212 Aspergillus Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000606125 Bacteroides Species 0.000 abstract 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 241000606153 Chlamydia trachomatis Species 0.000 abstract 1
- 241000588923 Citrobacter Species 0.000 abstract 1
- 241000193403 Clostridium Species 0.000 abstract 1
- 241000186216 Corynebacterium Species 0.000 abstract 1
- 241000588914 Enterobacter Species 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000186394 Eubacterium Species 0.000 abstract 1
- 241000223218 Fusarium Species 0.000 abstract 1
- 241001453172 Fusobacteria Species 0.000 abstract 1
- 241000588748 Klebsiella Species 0.000 abstract 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000186359 Mycobacterium Species 0.000 abstract 1
- 241000187917 Mycobacterium ulcerans Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 241000206591 Peptococcus Species 0.000 abstract 1
- 241000191992 Peptostreptococcus Species 0.000 abstract 1
- 241000186429 Propionibacterium Species 0.000 abstract 1
- 241000588769 Proteus <enterobacteria> Species 0.000 abstract 1
- 241000589516 Pseudomonas Species 0.000 abstract 1
- 241000607715 Serratia marcescens Species 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 230000002730 additional effect Effects 0.000 abstract 1
- 241001148470 aerobic bacillus Species 0.000 abstract 1
- 229940038705 chlamydia trachomatis Drugs 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000007938 effervescent tablet Substances 0.000 abstract 1
- 230000009841 epithelial lesion Effects 0.000 abstract 1
- 229960003276 erythromycin Drugs 0.000 abstract 1
- 239000006260 foam Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 150000004291 polyenes Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000011787 zinc oxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0104790A HU0104790D0 (en) | 2001-11-08 | 2001-11-08 | Pharmaceutical combinations for topical application |
| PCT/HU2002/000115 WO2003039559A1 (fr) | 2001-11-08 | 2002-11-08 | Combinaisons pharmaceutiques comportant un fongicide, un sulfonamide bacteriostatique et un compose anti-bacterien pour application topique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161802A0 true IL161802A0 (en) | 2005-11-20 |
Family
ID=89979873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16180202A IL161802A0 (en) | 2001-11-08 | 2002-11-08 | Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical applicatio |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7811599B2 (fr) |
| EP (1) | EP1467743B1 (fr) |
| AT (1) | ATE447409T1 (fr) |
| DE (1) | DE60234276D1 (fr) |
| HU (1) | HU0104790D0 (fr) |
| IL (1) | IL161802A0 (fr) |
| RU (1) | RU2291694C2 (fr) |
| WO (1) | WO2003039559A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094431B2 (en) * | 2000-10-12 | 2006-08-22 | Mickey L. Peshoff | Method of healing skin wounds in mammals and a composition therefor |
| MXPA05007722A (es) | 2003-01-24 | 2006-01-31 | Connetics Australia Pty Ltd | Espuma de fosfato de clindamicina. |
| US7186416B2 (en) | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
| GB0315671D0 (en) * | 2003-07-04 | 2003-08-13 | Chelsea And Westminster Nhs Tr | Improvements in or relating to organic compounds |
| US20070036731A1 (en) * | 2005-08-13 | 2007-02-15 | Collegium Pharmaceutical, Inc. | Topical Delivery with a Carrier Fluid |
| EA200700760A1 (ru) * | 2007-04-27 | 2008-08-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Средство для лечения заболеваний предстательной железы |
| US8709446B2 (en) * | 2009-07-03 | 2014-04-29 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | HYR1 as a target for active and passive immunization against Candida |
| KR102061486B1 (ko) | 2012-03-19 | 2020-01-03 | 시다라 세라퓨틱스, 인코포레이티드 | 에키노칸딘 계열의 화합물에 대한 투여 용법 |
| KR20150031471A (ko) | 2012-09-28 | 2015-03-24 | 산텐 세이야꾸 가부시키가이샤 | 마이봄샘 기능 부전 또는 마이봄샘 경색의 치료제 또는 예방제 |
| US8883747B1 (en) | 2013-10-09 | 2014-11-11 | Craig W. Carver | Topical antifungal compositions and methods of use thereof |
| CN104621551A (zh) * | 2013-11-07 | 2015-05-20 | 中国科学院兰州化学物理研究所 | 一种鹿血多肽泡腾片及其制备方法 |
| US9226890B1 (en) | 2013-12-10 | 2016-01-05 | Englewood Lab, Llc | Polysilicone base for scar treatment |
| CN105056184A (zh) * | 2015-08-10 | 2015-11-18 | 庄迎春 | 一种用于尖锐湿疣的中药及其制备方法 |
| WO2017120471A1 (fr) | 2016-01-08 | 2017-07-13 | Cidara Therapeutics, Inc. | Procédés de prévention et de traitement d'infections à pneumocystis |
| CN109154603A (zh) | 2016-03-16 | 2019-01-04 | 奇达拉治疗公司 | 用于治疗真菌感染的给药方案 |
| US20210002346A1 (en) * | 2016-11-29 | 2021-01-07 | Cidara Therapeutics, Inc | Methods for preventing fungal infections |
| WO2019014333A1 (fr) | 2017-07-12 | 2019-01-17 | Cidara Therapeutics, Inc. | Compositions et méthodes pour le traitement d'infections fongiques |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54140712A (en) | 1978-04-21 | 1979-11-01 | Yukio Yanagimoto | Sprayable scald treating drug |
| HU195618B (en) | 1981-03-17 | 1988-06-28 | Human Oltoanyagtermelo | Process for producing composition for treating epidermic lesions of skin |
| HU184410B (en) | 1981-03-17 | 1984-08-28 | Human Oltoanyagtermelo | Process for producing skin conditioning, regenerating or protecting composition facilitating epithelization |
| FR2542616B1 (fr) | 1983-03-17 | 1987-07-31 | Unilever Nv | Composition pour le traitement des muqueuses a base d'un antibiotique et d'un hydrocolloide formateur de gel |
| US4912124A (en) * | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| JPH01206937A (ja) * | 1988-02-16 | 1989-08-21 | Meidensha Corp | ミミズの養殖方法 |
| HU215443B (hu) * | 1994-07-25 | 1999-04-28 | Márton Milánkovits | Többféle hatóanyagot tartalmazó gyógyszerkészítmények, főként hüvelykúp, baktericid, fungicid, protozoa- és vírusellenes kombinált hatással |
| DE69716769T2 (de) | 1997-04-04 | 2003-06-12 | Human Oltoanyagtermeloe Es Gyo | Zubereitungen zur behandlung von verbrennungen und externen ulcera sowie verfahren zu deren herstellung |
-
2001
- 2001-11-08 HU HU0104790A patent/HU0104790D0/hu unknown
-
2002
- 2002-11-08 US US10/494,883 patent/US7811599B2/en not_active Expired - Fee Related
- 2002-11-08 WO PCT/HU2002/000115 patent/WO2003039559A1/fr not_active Application Discontinuation
- 2002-11-08 RU RU2004117593/15A patent/RU2291694C2/ru not_active IP Right Cessation
- 2002-11-08 AT AT02777587T patent/ATE447409T1/de not_active IP Right Cessation
- 2002-11-08 IL IL16180202A patent/IL161802A0/xx unknown
- 2002-11-08 DE DE60234276T patent/DE60234276D1/de not_active Expired - Lifetime
- 2002-11-08 EP EP02777587A patent/EP1467743B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1467743B1 (fr) | 2009-11-04 |
| ATE447409T1 (de) | 2009-11-15 |
| WO2003039559B1 (fr) | 2003-09-12 |
| DE60234276D1 (de) | 2009-12-17 |
| EP1467743A1 (fr) | 2004-10-20 |
| WO2003039559A1 (fr) | 2003-05-15 |
| US7811599B2 (en) | 2010-10-12 |
| RU2004117593A (ru) | 2005-04-20 |
| HU0104790D0 (en) | 2002-01-28 |
| US20050043222A1 (en) | 2005-02-24 |
| RU2291694C2 (ru) | 2007-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161802A0 (en) | Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical applicatio | |
| RU2529799C2 (ru) | Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения | |
| Spann et al. | Topical antibacterial agents for wound care: a primer | |
| EP1330221B1 (fr) | Compositions pharmaceutiques et pansements permettant de traiter les infections microbiennes de lésions cutanées | |
| US9314482B2 (en) | Methods and compositions for promoting wound healing | |
| Kaye | Topical antibacterial agents | |
| WO2005099655A2 (fr) | Compositions de nettoyage antimicrobiennes et methodes d'utilisation | |
| DE60134855D1 (de) | Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen | |
| AU5246699A (en) | Pharmaceutical compositions and methods for managing skin conditions | |
| US20040151765A1 (en) | Methods and compositions for wound management | |
| PT806941E (pt) | Composicoes anti-bacterianas liposomicas de rigidez baixa | |
| Marone et al. | Comparative in vitro activity of silver sulfadiazine, alone and in combination with cerium nitrate, against staphylococci and gram-negative bacteria | |
| US20180015061A1 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof | |
| CN106572662A (zh) | 抗微生物‑抗生物膜组合物及其作为个人护理产品的使用方法 | |
| ATE461928T1 (de) | Antibakterielle wirkstoffe | |
| Lio et al. | Topical antibacterial agents | |
| Lio et al. | Topical antibacterial agents | |
| Schimpff et al. | Infections in cancer patients: some controversial issues | |
| WO2004056346A1 (fr) | Procedes et compositions pour le traitement des plaies | |
| Hacker | Common infections of the skin: characteristics, causes, and cures | |
| Ivantsyk et al. | Advantages of the composition and actyvity of a new combined ointment with ethony for treatment of the wound process | |
| Kaye et al. | Topical antibacterial agents | |
| Van Furth et al. | Modulation of the host flora | |
| Piedrola et al. | Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 Gram-negative clinical isolates | |
| HUP0203876A2 (hu) | Topikális alkalmazású gyógyszerkombinációk |